Compare Natco Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA IPCA LABS NATCO PHARMA/
IPCA LABS
 
P/E (TTM) x 30.6 21.1 145.1% View Chart
P/BV x 4.4 7.5 57.7% View Chart
Dividend Yield % 0.8 0.2 482.7%  

Financials

 NATCO PHARMA   IPCA LABS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-19
IPCA LABS
Mar-19
NATCO PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs8491,042 81.5%   
Low Rs557590 94.4%   
Sales per share (Unadj.) Rs573.8298.6 192.2%  
Earnings per share (Unadj.) Rs176.035.0 502.9%  
Cash flow per share (Unadj.) Rs198.249.4 400.9%  
Dividends per share (Unadj.) Rs6.253.00 208.3%  
Dividend yield (eoy) %0.90.4 241.8%  
Book value per share (Unadj.) Rs842.7247.1 341.0%  
Shares outstanding (eoy) m36.50126.35 28.9%   
Bonus/Rights/Conversions BBESOS-  
Price / Sales ratio x1.22.7 44.8%   
Avg P/E ratio x4.023.3 17.1%  
P/CF ratio (eoy) x3.516.5 21.5%  
Price / Book Value ratio x0.83.3 25.3%  
Dividend payout %3.68.6 41.4%   
Avg Mkt Cap Rs m25,660103,108 24.9%   
No. of employees `0005.013.4 36.9%   
Total wages/salary Rs m3,5597,874 45.2%   
Avg. sales/employee Rs Th4,225.32,807.0 150.5%   
Avg. wages/employee Rs Th718.0585.8 122.6%   
Avg. net profit/employee Rs Th1,295.9329.0 393.9%   
INCOME DATA
Net Sales Rs m20,94537,732 55.5%  
Other income Rs m1,302577 225.7%   
Total revenues Rs m22,24738,309 58.1%   
Gross profit Rs m7,9486,901 115.2%  
Depreciation Rs m8101,824 44.4%   
Interest Rs m193189 102.3%   
Profit before tax Rs m8,2475,465 150.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8231,042 174.9%   
Profit after tax Rs m6,4244,422 145.3%  
Gross profit margin %37.918.3 207.5%  
Effective tax rate %22.119.1 115.9%   
Net profit margin %30.711.7 261.7%  
BALANCE SHEET DATA
Current assets Rs m23,47223,778 98.7%   
Current liabilities Rs m7,28710,975 66.4%   
Net working cap to sales %77.333.9 227.7%  
Current ratio x3.22.2 148.7%  
Inventory Days Days92104 88.9%  
Debtors Days Days8866 133.8%  
Net fixed assets Rs m18,64820,368 91.6%   
Share capital Rs m365253 144.4%   
"Free" reserves Rs m34,52530,971 111.5%   
Net worth Rs m30,76031,224 98.5%   
Long term debt Rs m01,409 0.0%   
Total assets Rs m43,03145,507 94.6%  
Interest coverage x43.730.0 146.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.8 58.7%   
Return on assets %15.410.1 151.8%  
Return on equity %20.914.2 147.5%  
Return on capital %27.417.3 158.4%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m11,53617,308 66.6%   
Fx outflow Rs m2,9396,266 46.9%   
Net fx Rs m8,59711,042 77.9%   
CASH FLOW
From Operations Rs m6,6884,923 135.9%  
From Investments Rs m-6,122-1,563 391.7%  
From Financial Activity Rs m-509-1,832 27.8%  
Net Cashflow Rs m661,528 4.3%  

Share Holding

Indian Promoters % 52.0 45.9 113.4%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 11.4 68.8%  
FIIs % 16.6 25.3 65.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.4 149.4%  
Shareholders   25,395 36,892 68.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   TTK HEALTHCARE  ALEMBIC  DR. REDDYS LAB  ELDER PHARMA  SUVEN LIFE SCIENCES  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Up 243 Points, Upcoming IPOs, NTPC-GAIL Share Purchase Agreement, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed huge buying interest during the extended closing hours yesterday and ended on a strong note.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 24, 2021 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS